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Background. In 2010, the Clinical and Laboratory Standards Institute (CLSI) lowered susceptibility breakpoints for carbapenem agents, though few studies have evaluated the clinical impact of these changes. The objective of this study was to determine whether a clinical breakpoint exists for carbapenems in patients with Gramnegative Enterobacteriaceaebloodstream infections (GNBSIs).
Methods. Patient-level data from 4 publications (Rhodes JN 2016 , Biehle LR 2015 , Patel TS 2015 , Esterly JS 2012 reporting outcomes for GNBSIs treated with carbapenems for ≥48 hours were compiled. Patients with an MIC ≥16 mg/L to both imipenem (IMI) and meropenem (MER) were excluded. Classification and Regression Tree (CART) analyses were used to determine optimal splits for carbapenem MIC with respect to 30-day all-cause mortality. Univariate and multivariate regression analyses were conducted using Stata 14.
Results. A total of 194 patients were extracted. Klebsiella pneumoniae was the most common pathogen (70.1%) followed by Escherichia coli(15.0%). Primary bacteremia/unknown and urinary tract were the most common sources of GNBSI (31.4% and 25.8%, respectively). MER and IMI MICs were available for 144 patients (74.2%) and 138 patients (71.1%), respectively. Carbapenem agent used was known for 141 patients, of which 94 received MER, 24 received ertapenem, 12 received doripenem, and 11 received IMI. CART analysis identified a significant difference in mortality between patients infected with organisms having MER MICs ≤ 1 mg/L (n = 10/121, 8.3%) vs. those with >1 mg/L (n = 7/21, 33.3%; P <0.01) regardless of carbapenem used. This breakpoint was also identified in the subgroup of patients with available MER MICs who were treated with MER (n = 5/64, 7.8% vs. 7/19, 36.8%; P < 0.01). In multivariate logistic regression, MER MIC > 1 mg/L was associated with increased odds of 30-day mortality after controlling for ICU admission in the any carbapenem treatment (OR 5.0, 95% CI 1.63-15.6; P < 0.01) and MER treated populations (OR 7.16, ; P < 0.01).
Conclusion. This pooled patient-level analysis of GNBSIs treated with carbapenems represents the largest of its kind to date. A significant increase in mortality was identified in patients with MER non-susceptible isolates as defined by the 2010 CLSI breakpoints.
Disclosures. Methods. Kaiser Permanente Northern California delivers care to 4 million members and is served by a centralized microbiological laboratory and an electronic medical record system. We identified patients hospitalized with a positive blood culture for ceftriaxone-resistant Escherichia coli, Klebsiella species and Proteus mirabilis between January 2008 and December 2015.
Patients were grouped as: Piperacillin-tazobactam (PTZ) group: received PTZ (and not carbapenem) OR initial therapy with PTZ followed by a switch to a carbapenem.
Carbapenem group: received carbapenem (and not PTZ) OR initial therapy with carbapenem followed by a switch to PTZ.
All isolates were ceftriaxone-resistant (surrogate for ESBL production) and susceptible to carbapenems and PTZ by invitro testing. Blood Stream Infection Mortality Risk Score (BSIMRS) was calculated for the 48 hour period of the positive blood culture.
Patients in the carbapenem group were matched 1:1 to patients in the PTZ group using a propensity score, which indicated the adjusted probability of being in the carbapenem group. Odds Ratio (OR) was calculated for 14 day mortality.
Results Background. C/T is a novel antipseudomonal cephalosporin, combined with tazobactam, an established β-lactamase inhibitor. C /T is approved for treatment of complicated urinary tract (cUTI) and complicated intraabdominal infections c(IAI). The objective is to provide real-world data describing the prescribing patterns of C/T and antimicrobial susceptibility profiles of the isolates in these patients (pts).
Methods. Patients from the Predictive Health Intelligence Environment were included, if they were hospitalized and prescribed C/T for greater than 48 hours between 1/14/15-5/1/17. Classification of infection type was based on diagnosis codes. Empiric was treatment given prior to culture results. Escalation was the addition of another GN antibiotic for at least 48 hours after initial GN therapy. Pan-β-lactam resistance (PBL-R) were isolates resistant to cefepime, ceftazidime, piperacillin/tazobactam, meropenem, and imipenem.
Results. 394 patients had 524 C/T encounters. The majority of the patients were male 235 (60%) and Caucasian 221 (56%) with an average age of 56 ± 17 years. Fifty percent of patients received antimicrobials within 30 days prior to the index hospitalization. Common comorbidities were chronic pulmonary disease 175 (44%), renal disease 140 (36%) and diabetes 132 (34%), with an average Charlson Comorbidity Index of 3.8 ± 3. A majority 350 (89%) of patients received C/T within the first week of hospitalization. Patients receiving C/T most commonly had respiratory infections 189 (48%), cUTI 163 (41%) and cIAI 107 (27%). The most common (317/394; 80%) isolated pathogen was Pseudomonas aeruginosa (PSA).The median and interquartile range of C/T duration was 9 (4-18) days. C/T was empiric for 77 patients and in 71 (18%) of patients C/T was the only GN therapy received. 110 (28%) were escalated to C/T after other GN therapy, 197 (50%) had some overlapping GN coverage and 14 (3.5%) patients received escalation after receipt of C/T. Susceptibility to CT was demonstrated in (69/75; 92%) of PSA including (65/71; 92%) of PBL-R isolates . Fig 1. Conclusion. C/T demonstrated high in vitro susceptibility, including against PBL-R isolates. Most patients received C/T for treatment of PSA and only a few patients required escalation of therapy after C/T. Background. Vancomycin-resistant Enterococci (VRE) is a well-known infectious complication among immunocompromised patients. VRE colonization of the gastro-intestinal (GI) tract could be associated with VRE bacteremia and worse outcome in hematopoietic cell transplant (HCT) recipients, in particular. Eradication of VRE colonization with systemic antibiotics is strongly discouraged for many reasons including lack of efficacy, rapid onset of resistance to the particular antibiotic used, and disruption of the normal site flora. Bacteriophages (phages) may constitute a good alternative to antibiotics to eliminate specific pathogens without disturbing the patient's normal flora. Phages are the most abundant organisms in the biosphere. They are naturally occurring entities that play a critical role in maintaining microbial balance in every ecosystem where bacteria are present.
Methods. Nine HCT recipients were enrolled in this study including 5 with no VRE infection or colonization, 3 with detected VRE colonization of the GI tract, and 1 with confirmed VRE bacteremia. One-time stool samples were obtained and screened for the presence of VRE-specific phages. Individual phage plaques were then harvested, amplified, and characterized. The recovered phages were tested against VRE strains isolated from the same stool samples.
Results. Five different phages were isolated from stool samples ( Figure 1A-C) . All phages were able to eradicate at least one of these VRE strains ( Figure 1D ). The action of some of these phages complemented one another. Phages 1 and 5 as well as phages 2 and 4 could form cocktails active against all these VRE strains.
Conclusion. Our results highlight the feasibility and the potential success of these phages in eradicating VRE in vitro and in vivo. The isolation of phages directly from patients' stool samples is a novel approach to obtain naturally-occurring phages already present in the gut. These VRE-specific phage cocktails may be used in future studies to eliminate VRE colonization and subsequent infections in HCT recipients.
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